<DOC>
	<DOCNO>NCT02669433</DOCNO>
	<brief_summary>This study seek evaluate efficacy safety intepirdine ( RVT-101 ) patient dementia Lewy body .</brief_summary>
	<brief_title>Study Evaluating Intepirdine ( RVT-101 ) Subjects With Dementia With Lewy Bodies : The HEADWAY-DLB Study</brief_title>
	<detailed_description>The efficacy safety RVT-101 dose 70 mg 35 mg daily evaluate 24-week double-blind treatment period patient dementia Lewy body . The randomization ratio 1:1:1 ( 70 mg RVT-101 : 35 mg RVT-101 : placebo ) . Subjects complete study eligible enroll extension study RVT-101 ( Study RVT-101-2002 ) .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Male female subject probable DLB Mini Mental State Examination ( MMSE ) score 1426 inclusive Screening Baseline Patient ability comply procedure cognitive test opinion investigator Patient reliable caregiver willing report subject 's status throughout study Patients currently receive therapy DLB eligible enrollment Atypical clinical feature clinical course would lead investigator conclude primary symptom likely explain alternate dementia diagnosis . Any clinically relevant concomitant disease , opinion investigator , make patient unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Lewy body</keyword>
	<keyword>intepirdine</keyword>
	<keyword>RVT-101</keyword>
	<keyword>dementia</keyword>
</DOC>